This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bedarida, G. V. Articles by Hoffman, B. B. Search for Related Content PubMed PubMed Citation Articles by Bedarida, G. V. Articles by Hoffman, B. B.

Circulation, Vol 88, 2754-2761, Copyright © 1993 by American Heart Association

ARTICLES

Responsiveness to bradykinin in veins of hypercholesterolemic humans

GV Bedarida, E Bushell, WE Haefeli, TF Blaschke and BB Hoffman
Division of Clinical Pharmacology, Stanford University Medical Center, CA 94305-5113.

BACKGROUND. Hypercholesterolemia impairs endothelium-dependent dilation in arteries. We tested the hypothesis that hypercholesterolemia impairs endothelium-dependent vasodilation by an interaction between elevated plasma lipoproteins and a presumably normal endothelium using human veins in vivo; veins do not generally develop atherosclerosis and are appropriate for testing functional alterations. METHODS AND RESULTS. Full dose-response curves were constructed in 13 hypercholesterolemic and 12 normocholesterolemic subjects by infusing bradykinin (0.25 to 508 ng/min) into hand veins preconstricted with the alpha-adrenergic agonist phenylephrine. The maximal relaxation induced by bradykinin was 80 +/- 38% in the controls and 103 +/- 40% in subjects with hypercholesterolemia (P = .08). Responsiveness to bradykinin was also determined after infusion of indomethacin (5.4 micrograms/min), a cyclooxygenase inhibitor, to block the contribution of prostaglandins; maximal responsiveness was greater in hypercholesterolemic subjects (112 +/- 41%) than in controls (81 +/- 31%) (P = .03). Hypercholesterolemic subjects were more sensitive to bradykinin, with an ED50 of 4.2 ng/min versus 10.9 ng/min in controls (P = .05); a similarly increased sensitivity was found in the presence of indomethacin. The response to a maximally effective dose of nitroglycerin was greater in hypercholesterolemic subjects (142 +/- 31%) versus 106 +/- 28% in controls (P = .007). In five hypercholesterolemic subjects, treated with lovastatin to normalize serum cholesterol concentrations, maximal responsiveness to bradykinin decreased from 103 +/- 52% to 80 +/- 28%. CONCLUSIONS. These results demonstrate that hypercholesterolemia in humans does not impair endothelium-derived relaxing factor-mediated venodilation.

This article has been cited by other articles:

				E. R. Rabelo, K. Ruschel, H. Moreno Jr., M. Rubira, F. M. Consolim-Colombo, M. C. Irigoyen, and L. E. Rohde Venous endothelial function in heart failure: Comparison with healthy controls and effect of clinical compensation Eur J Heart Fail, August 1, 2008; 10(8): 758 - 764. [Abstract] [Full Text] [PDF]

				T. V. Lewis, A. M. Dart, and J. P. F. Chin-Dusting Endothelium-dependent relaxation by acetylcholine is impaired in hypertriglyceridemic humans with normal levels of plasma LDL cholesterol J. Am. Coll. Cardiol., March 1, 1999; 33(3): 805 - 812. [Abstract] [Full Text] [PDF]

				H. Moreno Jr., S. Chalon, A. Urae, O. Tangphao, A. K. Abiose, B. B. Hoffman, and T. F. Blaschke Endothelial dysfunction in human hand veins is rapidly reversible after smoking cessation Am J Physiol Heart Circ Physiol, September 1, 1998; 275(3): H1040 - H1045. [Abstract] [Full Text] [PDF]

				L. Linder, B. M. Lautenschlager, and W. E. Haefeli Subconstrictor Doses of Neuropeptide Y Potentiate {alpha}1-Adrenergic Venoconstriction In Vivo Hypertension, September 1, 1996; 28(3): 483 - 487. [Abstract] [Full Text]